

# Our Patient Access Philosophy & 2025 Progress

Throughout our 20+ year journey in developing RNAi therapeutics, we have remained focused on keeping patients at the center of everything we do. Beyond accepting the challenges of scientific discovery and development, we believe that we are accountable for ensuring that patients who can benefit from our medicines have access to them.

Our **Patient Access Philosophy**, established in 2017 – before our first medicine was approved – continues to guide us, holding us accountable for ensuring that access and outcomes align with the value our therapies bring to patients.

We report on our progress annually. The data covers the period through 2025.

## Sustainable Value and Significant Impact

We believe it is our responsibility to push the boundaries of scientific discovery, clinical development, and delivery to fuel significant, sustainable patient impact.

**\$0**

in out-of-pocket costs for a majority of patients

**>95%**

of U.S. residents with confirmed access to our therapies across commercial, Medicare, Medicaid, and other government payers

**70+**

countries where patients can access our therapies by way of direct or distributor infrastructure

**~90%**

of patients have first-line access to AMVUTTRA®

**960+**

patients who have received Alnylam therapeutics under compassionate use

**~90%**

of patients can receive AMVUTTRA® treatment within ~10 miles of where they live

**93%**

of EU countries have access to at least one of our therapies

## Connecting to Achieve Better Outcomes

We believe that together with partners in the healthcare ecosystem, we can reduce barriers to our medicines to improve outcomes for all stakeholders in the patient journey – most importantly, for the patients who may benefit from them.

**4,000+**

U.S. patients enrolled in Alnylam Assist®

**31**

patient voice inclusion interviews

**5,200+**

patients participating in clinical trials for our therapies

**6,300+**

personalized patient touchpoints by Patient Education Liason (PEL) team

**55**

value-based agreements signed with U.S. payers across therapies

*Continued on back page*

## Proactive and Accountable

We believe that biopharmaceutical companies play a critical role in the patient's journey to accessing innovative therapeutic options and should be accountable for progress.

**208**

patient advocacy events  
supported worldwide

**15**

U.S. outcome initiatives for  
patients with hATTR-PN and  
ATTR-CM implemented with  
large health systems

**134,000+**

samples genotyped through  
Alnylam Act® or GeneAct™  
since the programs began

**98**

patient advocacy groups  
supported worldwide

## Patient Access and Support

Through various programs, we provide patients with access to diagnostic resources and genetic testing with the goal of removing barriers for patients to access to our commercially available therapies. In addition, we enable access to our investigational drugs for treatment outside clinical trials when no comparable or satisfactory alternative therapy options are available.

### Our key programs include:

- **Alnylam Act®** offers eligible patients in the U.S., Canada, and Brazil no-charge, third-party genetic testing and counseling.\*
- **GeneAct™** offers third-party genetic testing in selected countries across Europe and Middle East.\*
- **Alnylam's Compassionate Use Policy** outlines the circumstances in which we will consider providing treatment for an individual patient outside a clinical trial. We evaluate all requests in a fair and equitable manner.
- Since Alnylam's first commercial launch in 2018, **Alnylam Assist®** has supported patients throughout their journey, offering best-in-class patient support services. Staffed by Alnylam employees solely dedicated to supporting patients and providers in our disease states, this model has enabled our team to develop a deep understanding of the patient journey and expertly manage treatment initiation, access and reimbursement, and financial assistance.

Statistics reflect Alnylam Data on File

\* Healthcare professionals or patients who use these programs have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Alnylam product

For more information on Alnylam's approach to access and affordability, please visit [alnylam.com/access](https://alnylam.com/access)

